Clinical Trial Update: Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study of obinutuzumab in combination with CC-99282 for previously untreated high tumor burden follicular lymphoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• CC-99282
• Gazyva (Obinutuzumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Follicular Lymphoma, Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING